163 related articles for article (PubMed ID: 26335936)
1. The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.
Normanno N; Pinto C; Castiglione F; Fenizia F; Barberis M; Marchetti A; Fontanini G; De Rosa G; Taddei GL
J Transl Med; 2015 Sep; 13():287. PubMed ID: 26335936
[TBL] [Abstract][Full Text] [Related]
2. External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.
Tack V; Ligtenberg MJ; Tembuyser L; Normanno N; Vander Borght S; Han van Krieken J; Dequeker EM
Oncologist; 2015 Mar; 20(3):257-62. PubMed ID: 25657200
[TBL] [Abstract][Full Text] [Related]
3. Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer.
Normanno N; Pinto C; Taddei G; Gambacorta M; Castiglione F; Barberis M; Clemente C; Marchetti A
J Thorac Oncol; 2013 Jun; 8(6):773-8. PubMed ID: 23575414
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.
Normanno N; Pinto C; Castiglione F; Bardelli A; Gambacorta M; Botti G; Nappi O; Siena S; Ciardiello F; Taddei G; Marchetti A
PLoS One; 2011; 6(12):e29146. PubMed ID: 22216189
[TBL] [Abstract][Full Text] [Related]
5. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.
Bellon E; Ligtenberg MJ; Tejpar S; Cox K; de Hertogh G; de Stricker K; Edsjö A; Gorgoulis V; Höfler G; Jung A; Kotsinas A; Laurent-Puig P; López-Ríos F; Hansen TP; Rouleau E; Vandenberghe P; van Krieken JJ; Dequeker E
Oncologist; 2011; 16(4):467-78. PubMed ID: 21441573
[TBL] [Abstract][Full Text] [Related]
6. Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.
Tembuyser L; Ligtenberg MJ; Normanno N; Delen S; van Krieken JH; Dequeker EM
J Mol Diagn; 2014 May; 16(3):371-7. PubMed ID: 24631467
[TBL] [Abstract][Full Text] [Related]
7. Results of first proficiency test for KRAS testing with formalin-fixed, paraffin-embedded cell lines in China.
Zhang R; Han Y; Huang J; Ma L; Li Y; Li J
Clin Chem Lab Med; 2014 Dec; 52(12):1851-7. PubMed ID: 24945428
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma.
Ishige T; Itoga S; Sato K; Kitamura K; Nishimura M; Sawai S; Matsushita K; Suzuki K; Ota S; Miyauchi H; Matsubara H; Nakatani Y; Nomura F
Clin Biochem; 2014 Dec; 47(18):340-3. PubMed ID: 25262986
[TBL] [Abstract][Full Text] [Related]
9. Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis.
Dijkstra JR; Opdam FJ; Boonyaratanakornkit J; Schönbrunner ER; Shahbazian M; Edsjö A; Hoefler G; Jung A; Kotsinas A; Gorgoulis VG; López-Ríos F; de Stricker K; Rouleau E; Biesmans B; van Krieken JH
J Mol Diagn; 2012; 14(3):187-91. PubMed ID: 22414609
[TBL] [Abstract][Full Text] [Related]
10. Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment.
Deans ZC; Bilbe N; O'Sullivan B; Lazarou LP; de Castro DG; Parry S; Dodson A; Taniere P; Clark C; Butler R
J Clin Pathol; 2013 Apr; 66(4):319-25. PubMed ID: 23378269
[TBL] [Abstract][Full Text] [Related]
11. Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples.
Cortes U; Guilloteau K; Rouvreau M; Archaimbault C; Villalva C; Karayan-Tapon L
Exp Mol Pathol; 2015 Oct; 99(2):207-11. PubMed ID: 26163758
[TBL] [Abstract][Full Text] [Related]
12. RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016).
Richman SD; Fairley J; Butler R; Deans ZC
Virchows Arch; 2017 Dec; 471(6):721-729. PubMed ID: 28653203
[TBL] [Abstract][Full Text] [Related]
13. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme.
Marchetti A; Barberis M; Papotti M; Rossi G; Franco R; Malatesta S; Buttitta F; Ardizzoni A; Crinò L; Gridelli C; Taddei GL; Clemente C; Scagliotti G; Normanno N; Pinto C
J Thorac Oncol; 2014 Oct; 9(10):1470-6. PubMed ID: 25170637
[TBL] [Abstract][Full Text] [Related]
14. RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.
Boleij A; Tack V; Taylor A; Kafatos G; Jenkins-Anderson S; Tembuyser L; Dequeker E; van Krieken JH
BMC Cancer; 2016 Oct; 16(1):825. PubMed ID: 27784278
[TBL] [Abstract][Full Text] [Related]
15. RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment.
Tack V; Ligtenberg MJL; Siebers AG; Rombout PDM; Dabir PD; Weren RDA; van Krieken JHJM; Dequeker EMC
Virchows Arch; 2018 May; 472(5):717-725. PubMed ID: 29333594
[TBL] [Abstract][Full Text] [Related]
16. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.
Feigelson HS; Goddard KA; Johnson MA; Funk KC; Rahm AK; Kauffman TL; Chitale DA; Le Marchand L; Richards CS
BMC Res Notes; 2012 Apr; 5():196. PubMed ID: 22534075
[TBL] [Abstract][Full Text] [Related]
17. Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer.
Dequeker EM; Keppens C; Egele C; Delen S; Lamy A; Lemoine A; Sabourin JC; Andrieu C; Ligtenberg M; Fetique D; Tops B; Descarpentries C; Blons H; Denoux Y; Aube C; Penault-Llorca F; Hofman P; Leroy K; Le Marechal C; Doucet L; Duranton-Tanneur V; Pedeutour F; Soubeyran I; Côté JF; Emile JF; Vignaud JM; Monhoven N; Haddad V; Laurent-Puig P; van Krieken H; Nowak F; Lonchamp E; Bellocq JP; Rouleau E
J Mol Diagn; 2016 Mar; 18(2):205-14. PubMed ID: 26752307
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme.
Dequeker E; Ligtenberg MJ; Vander Borght S; van Krieken JH
Virchows Arch; 2011 Aug; 459(2):155-60. PubMed ID: 21701884
[TBL] [Abstract][Full Text] [Related]
19. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study.
Yoshino T; Muro K; Yamaguchi K; Nishina T; Denda T; Kudo T; Okamoto W; Taniguchi H; Akagi K; Kajiwara T; Hironaka S; Satoh T
EBioMedicine; 2015 Apr; 2(4):317-23. PubMed ID: 26137573
[TBL] [Abstract][Full Text] [Related]
20. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
